Postpartum Disorders

Review the latest in psychiatry from the last week.

Recognize postpartum psychosis fast: early signs, key risk factors, OCD vs delusions, and evidence-based lithium-centered treatment for urgent care.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

Learn how clinicians manage bipolar disorder in women who may become pregnant—safer meds, contraception counseling, and relapse prevention.

Learn how fast-acting oral zuranolone treats postpartum depression in days, with practical prescribing and breastfeeding guidance clinicians can use.

MRI-guided SAINT TMS aims to remit treatment-resistant depression in days.

Guidance on psychotropic meds in pregnancy: personalize decisions, coordinate care, and plan early to prevent postpartum relapse.

Planning for prevention of perinatal psychiatric relapse with safer medication options.

A multicenter study tests SAINT TMS for postpartum depression.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

Study shows brief interpersonal therapy during pregnancy cuts depression through year postpartum.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

LPCN 1154 shows promise as a rapid, at-home treatment for postpartum depression, with favorable safety results in ongoing phase 3 trials.